Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

68Ga–Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma

A Potential Biomarker for Targeted Radioligand Therapy?

Marafi, Fahad, KBNM*; Usmani, Sharjeel, MBBS, MS, FEBNM, CBNC*†; Esmail, Abdulredha, KBNM*

doi: 10.1097/RLU.0000000000002563
Interesting Images

68Ga-PSMA is a promising tracer for both staging and detection of biochemical recurrence in prostate cancer. Prostate-specific membrane antigen is also expressed in the endothelium of neovasculature of various solid malignancies possibly due to tumor-associated angiogenic factors and endothelial cell sprouting. We report a case of 75-year-old man with metastatic cholangiocarcinoma to liver and lymph nodes progressing on chemotherapy. 68Ga-PSMA PET/CT was performed to assess PSMA expression and showed additional bone and hepatic lesions compared with 18F-FDG PET/CT. 68Ga-PSMA expression in the metastatic cholangiocarcinoma potentially guides radionuclide legend therapy with α/β-emitters especially after enervation of all approved therapeutic options.

From the *Nuclear Medicine Department, Jaber Al-Ahmad Molecular Imaging Center; and

Nuclear Medicine Department, Kuwait Cancer Control Center, Kuwait.

Received for publication December 27, 2018; revision accepted February 14, 2019.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Sharjeel Usmani, MBBS, MS, FEBNM, CBNC, Department of Nuclear Medicine, Kuwait Cancer Control Center, PO Box 1488, 83001 Khaitan, Kuwait. E-mail:

Online date: April 15, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.